Vitamin D: Methods of 25 hydroxyvitamin D analysis, targeting at risk populations and selecting thresholds of treatment

Clinical Biochemistry

Volumn 45, Issue 12, 2012, Pages 901-906

  Glendenning, Paul ^a,b,c   Inderjeeth, Charles A ^b,d  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d North Metropolitan Health Service   (Australia)

Author keywords

25OHD target of treatment; Methods of 25OHD analysis; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CALCIUM; DEOXYPYRIDINOLINE; HYDROXYPROLINE; PARATHYROID HORMONE;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ASTHMA; AUTOCRINE EFFECT; BONE BIOPSY; BONE DENSITOMETRY; BONE DENSITY; BONE TURNOVER; CALCIUM ABSORPTION; CALCIUM HOMEOSTASIS; CANCER RISK; CARDIOVASCULAR DISEASE; CLOTHING; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FALLING; FRACTIONAL CALCIUM ABSORPTION; FRACTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK PATIENT; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; HYDROXYPROLINE URINE LEVEL; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSULIN RESISTANCE; INTESTINE ABSORPTION; LIQUID CHROMATOGRAPHY; MALABSORPTION; META ANALYSIS (TOPIC); MULTIPLE SCLEROSIS; OBESITY; OSTEOMALACIA; PARACRINE SIGNALING; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; SKIN CANCER; SKIN COLOR; SOLID TUMOR; TANDEM MASS SPECTROMETRY; ULTRAVIOLET RADIATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

ANIMALS; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; BONE DENSITY; CALCIFEDIOL; DIETARY SUPPLEMENTS; HUMANS; REFERENCE STANDARDS; REFERENCE VALUES; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84863865511     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.04.002     Document Type: Review

References (76)

1. Chapuy M.C., Arlot M.E., Duboeuf F., Brun J., Crouzet B., Arnaud S., et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992, 327:1637-1642.
2. Dawson-Hughes B., Harris S.S., Krall E.A., Dallal G.E. Effect of calcium and vitamin D supplementation on bone density in men and women 65years of age or older. N Engl J Med 1997, 337:670-676.
3. Inderjeeth C.A., Glennon D., Petta A., Soderstrom J., Boyatzis I., Tapper J. Vitamin D and muscle strength in patients with previous fractures. N Z Med J 2007, 120:U2730.
4. Bischoff-Ferrari H.A., Dawson-Hughes B., Willett W.C., Staehelin H.B., Bazemore M.G., Zee R.Y., et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004, 291:1999-2006.
5. Lips P. Relative value of 25(OH)D and 1,25(OH)2D measurements. J Bone Miner Res 2007, 22:1668-1671.
6. Wharton B., Rickets Bishop N. Lancet 2003, 362:1389-1400.
7. Aaron J.E., Gallagher J.C., Anderson J., Stasiak L., Longton E.B., Nordin B.E., et al. Frequency of osteomalacia and osteoporosis in fractures of the proximal femur. Lancet 1974, 1:229-233.
8. Aaron J.E., Gallagher J.C., Nordin B.E. Seasonal variation of histological osteomalacia in femoral-neck fractures. Lancet 1974, 2:84-85.
9. Baker M.R., McDonnell H., Peacock M., Nordin B.E. Plasma 25-hydroxy vitamin D concentrations in patients with fractures of the femoral neck. Br Med J 1979, 1:589.
10. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001, 22:477-501.
11. Priemel M., von Domarus C., Klatte T.O., Kessler S., Schlie J., Meier S., et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res 2010, 25:305-312.
12. Heaney R.P., Dowell M.S., Hale C.A., Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003, 22:142-146.
13. Hansen K.E., Jones A.N., Lindstrom M.J., Davis L.A., Engelke J.A., Shafer M.M. Vitamin D insufficiency: disease or no disease?. J Bone Miner Res 2008, 23:1052-1060.
14. Malabanan A., Veronikis I.E., Holick M.F. Redefining vitamin D insufficiency. Lancet 1998, 351:805-806.
15. Lips P., Chapuy M.C., Dawson-Hughes B., Pols H.A., Holick M.F. An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int 1999, 9:394-397.
16. Steingrimsdottir L., Gunnarsson O., Indridason O.S., Franzson L., Sigurdsson G. Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA 2005, 294:2336-2341.
17. Bjorkman M., Sorva A., Tilvis R. Responses of parathyroid hormone to vitamin D supplementation: a systematic review of clinical trials. Arch Gerontol Geriatr 2009, 48:160-166.
18. Kuchuk N.O., Pluijm S.M., van Schoor N.M., Looman C.W., Smit J.H., Lips P. Relationships of serum 25-hydroxyvitamin D to bone mineral density and serum parathyroid hormone and markers of bone turnover in older persons. J Clin Endocrinol Metab 2009, 94:1244-1250.
19. Jesudason D., Need A.G., Horowitz M., O'Loughlin P.D., Morris H.A., Nordin B.E. Relationship between serum 25-hydroxyvitamin D and bone resorption markers in vitamin D insufficiency. Bone 2002, 31:626-630.
20. Bischoff-Ferrari H.A., Dietrich T., Orav E.J., Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med 2004, 116:634-639.
21. Ensrud K.E., Taylor B.C., Paudel M.L., Cauley J.A., Cawthon P.M., Cummings S.R., et al. Serum 25-hydroxyvitamin D levels and rate of hip bone loss in older men. J Clin Endocrinol Metab 2009, 94:2773-2780.
22. Cauley J.A., Lacroix A.Z., Wu L., Horwitz M., Danielson M.E., Bauer D.C., et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 2008, 149:242-250.
23. Prince R.L., Austin N., Devine A., Dick I.M., Bruce D., Zhu K. Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Arch Intern Med 2008, 168:103-108.
24. Bischoff-Ferrari H.A., Dawson-Hughes B., Staehelin H.B., Orav J.E., Stuck A.E., Theiler R., et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009, 339:b3692.
25. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., Gordon C.M., Hanley D.A., Heaney R.P., et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011, 96:1911-1930.
26. Dawson-Hughes B., Mithal A., Bonjour J.P., Boonen S., Burckhardt P., Fuleihan G.E., et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos Int 2010, 21:1151-1154.
27. Slomski A. IOM endorses vitamin D, calcium only for bone health, dispels deficiency claims. JAMA 2011, 305:453-454. 56.
28. Glendenning P., Zhu K., Inderjeeth C., Howat P., Lewis J.R., Prince R.L. Effects of three monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility and muscle strength in older postmenopausal women: a randomised controlled trial. J Bone Miner Res 2011, 27:170-176.
29. Sanders K.M., Stuart A.L., Williamson E.J., Simpson J.A., Kotowicz M.A., Young D., et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010, 303:1815-1822.
30. Smith H., Anderson F., Raphael H., Maslin P., Crozier S., Cooper C. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women-a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford) 2007, 46:1852-1857.
31. Lips P., Bouillon R., van Schoor N.M., Vanderschueren D., Verschueren S., Kuchuk N., et al. Reducing fracture risk with calcium and vitamin D. Clin Endocrinol (Oxf) 2010, 73:277-285.
32. Flicker L., Mead K., MacInnis R.J., Nowson C., Scherer S., Stein M.S., et al. Serum vitamin D and falls in older women in residential care in Australia. J Am Geriatr Soc 2003, 51:1533-1538.
33. Sambrook P.N., Cameron I.D., Cumming R.G., Lord S.R., Schwarz J.M., Trube A., et al. Vitamin D deficiency is common in frail institutionalised older people in northern Sydney. MJA 2002, 176:560.
34. Grover S.R., Morley R. Vitamin D deficiency in veiled or dark-skinned pregnant women. MJA 2001, 175:251-252.
35. Kimlin M., Harrison S., Nowak M., Moore M., Brodie A., Lang C. Does a high UV environment ensure adequate vitamin D status?. J Photochem Photobiol B 2007, 89:139-147.
36. McCombie A.M., Mason R.S., Damian D.L. Vitamin D deficiency in Sydney skin cancer patients. MJA 2009, 190:102.
37. Grethen E., McClintock R., Gupta C.E., Jones R., Cacucci B.M., Diaz D., et al. Vitamin d and hyperparathyroidism in obesity. J Clin Endocrinol Metab 2011, 96:1320-1326.
38. Nuti R., Martini G., Valenti R., Giovani S., Salvadori S., Avanzati A. Prevalence of undiagnosed coeliac syndrome in osteoporotic women. J Intern Med 2001, 250:361-366.
39. Thomas M.K., Lloyd-Jones D.M., Thadhani R.I., Shaw A.C., Deraska D.J., Kitch B.T., et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998, 338:777-783.
40. Boudville N., Inderjeeth C., Elder G.J., Glendenning P. Association between 25-hydroxyvitamin D, somatic muscle weakness and falls risk in end-stage renal failure. Clin Endocrinol (Oxf) 2010, 73:299-304.
41. Noble J.M., McGuiness M., Glendenning P. Low rate of compliance with ergocalciferol therapy in vitamin-D-deficient patients with hip fracture. MJA 2002, 177:280.
42. Seymour H.M., Glendenning P. Fit for a fracture. MJA 2005, 183:213-214.
43. Glendenning P. Diagnosis of primary hyperparathyroidism: controversies, practical issues and the need for Australian guidelines. Intern Med J 2003, 33:598-603.
44. Vasikaran S.D., Sturdy G., Musk A.A., Flicker L. Vitamin D insufficiency and hyperparathyroidism in Perth blood donors. MJA 2000, 172:406-407.
45. Mitri J., Muraru M.D., Pittas A.G. Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr 2011, 65:1005-1015.
46. Gandini S., Boniol M., Haukka J., Byrnes G., Cox B., Sneyd M.J., et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011, 128:1414-1424.
47. Souberbielle J.C., Body J.J., Lappe J.M., Plebani M., Shoenfeld Y., Wang T.J., et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev 2010, 9:709-715.
48. Manson J.E., Mayne S.T., Clinton S.K. Vitamin D and prevention of cancer-ready for prime time?. N Engl J Med 2011, 364:1385-1387.
49. Chlebowski R.T., Wactawski-Wende J., Ritenbaugh C., Hubbell F.A., Ascensao J., Rodabough R.J., et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004, 350:991-1004.
50. Lappe J.M., Travers-Gustafson D., Davies K.M., Recker R.R., Heaney R.P. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007, 85:1586-1591.
51. Haddad J.G., Chyu K.J. Competitive protein-binding radioassay for 25-hydroxycholecalciferol. J Clin Endocrinol Metab 1971, 33:992-995.
52. Belsey R., Deluca H.F., Potts J.T. Competitive binding assay for vitamin D and 25-OH vitamin D. J Clin Endocrinol Metab 1971, 33:554-557.
53. Eisman J.A., Shepard R.M., DeLuca H.F. Determination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 in human plasma using high-pressure liquid chromatography. Anal Biochem 1977, 80:298-305.
54. Jones G. Assay of vitamins D2 and D3, and 25-hydroxyvitamins D2 and D3 in human plasma by high-performance liquid chromatography. Clin Chem 1978, 24:287-298.
55. Hollis B.W., Napoli J.L. Improved radioimmunoassay for vitamin D and its use in assessing vitamin D status. Clin Chem 1985, 31:1815-1819.
56. Cavalier E., Huberty V., Cormier C., Souberbielle J.C. Overestimation of the 25(OH)D serum concentration with the automated IDS EIA kit. J Bone Miner Res 2011, 26:434-436.
57. Glendenning P. Issues of standardization and assay-specific clinical decision limits for the measurement of 25-hydroxyvitamin D. Am J Clin Nutr 2003, 77:522-523.
58. Roth H.J., Zahn I., Alkier R., Schmidt H. Validation of the first automated chemiluminescence protein-binding assay for the detection of 25-hydroxycalciferol. Clin Lab 2001, 47:357-365.
59. Glendenning P., Noble J.M., Taranto M., Musk A.A., McGuiness M., Goldswain P.R., et al. Issues of methodology, standardization and metabolite recognition for 25-hydroxyvitamin D when comparing the DiaSorin radioimmunoassay and the Nichols Advantage automated chemiluminescence protein-binding assay in hip fracture cases. Ann Clin Biochem 2003, 40:546-551.
60. Cluse Z.N., Fudge A.N., Whiting M.J., McWhinney B., Parkinson I., O'Loughlin P.D. Evaluation of 25-hydroxyvitamin D assay on the immunodiagnostics systems iSYS analyser. Ann Clin Biochem 2012, 49:159-165.
61. Connell A.B., Jenkins N., Black M., Pasco J.A., Kotowicz M.A., Schneider H.G. Overreporting of vitamin D deficiency with the Roche Elecsys Vitamin D3 (25-OH) method. Pathology 2011, 43:368-371.
62. Carter G.D., Carter R., Jones J., Berry J. How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. Clin Chem 2004, 50:2195-2197.
63. Cavalier E., Wallace A.M., Carlisi A., Chapelle J.P., Delanaye P., Souberbielle J.C. Cross-reactivity of 25-hydroxy vitamin D2 from different commercial immunoassays for 25-hydroxy vitamin D: an evaluation without spiked samples. Clin Chem Lab Med 2011, 49:555-558.
64. Glendenning P. Vitamin D deficiency and multicultural Australia. MJA 2002, 176:242-243. author reply 43.
65. Glendenning P., Taranto M., Noble J.M., Musk A.A., Hammond C., Goldswain P.R., et al. Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays. Ann Clin Biochem 2006, 43:23-30.
66. Glendenning P., Chew G.T., Seymour H.M., Gillett M.J., Goldswain P.R., Inderjeeth C.A., et al. Serum 25-hydroxyvitamin D levels in vitamin D-insufficient hip fracture patients after supplementation with ergocalciferol and cholecalciferol. Bone 2009, 45:870-875.
67. Stepman H.C., Vanderroost A., Van Uytfanghe K., Thienpont L.M. Candidate reference measurement procedures for serum 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 by using isotope-dilution liquid chromatography-tandem mass spectrometry. Clin Chem 2011, 57:441-448.
68. Kamao M., Tatematsu S., Hatakeyama S., Sakaki T., Sawada N., Inouye K., et al. C-3 epimerization of vitamin D3 metabolites and further metabolism of C-3 epimers: 25-hydroxyvitamin D3 is metabolized to 3-epi-25-hydroxyvitamin D3 and subsequently metabolized through C-1alpha or C-24 hydroxylation. J Biol Chem 2004, 279:15897-15907.
69. Singh R.J., Taylor R.L., Reddy G.S., Grebe S.K. C-3 epimers can account for a significant proportion of total circulating 25-hydroxyvitamin D in infants, complicating accurate measurement and interpretation of vitamin D status. J Clin Endocrinol Metab 2006, 91:3055-3061.
70. Harant H., Spinner D., Reddy G.S., Lindley I.J. Natural metabolites of 1alpha,25-dihydroxyvitamin D(3) retain biologic activity mediated through the vitamin D receptor. J Cell Biochem 2000, 78:112-120.
71. Fleet J.C., Bradley J., Reddy G.S., Ray R., Wood R.J. 1 alpha,25-(OH)2-vitamin D3 analogs with minimal in vivo calcemic activity can stimulate significant transepithelial calcium transport and mRNA expression in vitro. Arch Biochem Biophys 1996, 329:228-234.
72. Stepman H.C., Vanderroost A., Stockl D., Thienpont L.M. Full-scan mass spectral evidence for 3-epi-25-hydroxyvitamin D in serum of infants and adults. Clin Chem Lab Med 2011, 49:253-256.
73. Maunsell Z., Wright D.J., Rainbow S.J. Routine isotope-dilution liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of the 25-hydroxy metabolites of vitamins D2 and D3. Clin Chem 2005, 51:1683-1690.
74. Shah I., James R., Barker J., Petroczi A., Naughton D.P. Misleading measures in Vitamin D analysis: a novel LC-MS/MS assay to account for epimers and isobars. Nutr J 2011, 10:46.
75. Carter G.D., Jones J.C. Use of a common standard improves the performance of liquid chromatography-tandem mass spectrometry methods for serum 25-hydroxyvitamin-D. Ann Clin Biochem 2009, 46:79-81.
76. Roth H.J., Schmidt-Gayk H., Weber H., Niederau C. Accuracy and clinical implications of seven 25-hydroxyvitamin D methods compared with liquid chromatography-tandem mass spectrometry as a reference. Ann Clin Biochem 2008, 45:153-159.